Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mefenamic acid + drotaverine
- Development stage
- Unknown
- Lead developer
- Northland Bioscience
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mefenamic acid + drotaverine is a fixed-dose combination of a non-steroidal anti-inflammatory drug (NSAID) and an antispasmodic agent. Mefenamic acid acts by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis to alleviate pain and inflammation. Drotaverine is a benzylisoquinoline derivative that acts as a selective phosphodiesterase IV (PDE4) inhibitor, increasing intracellular cyclic AMP levels in smooth muscle cells to induce relaxation. This combination is primarily indicated for the symptomatic relief of spasmodic pain associated with conditions such as primary dysmenorrhea, biliary colic, renal colic, and gastrointestinal spasms. It is marketed by various manufacturers, including Northland Bioscience's subsidiary NBS Pharmaceuticals, typically in oral tablet form.
- Brand names
- Meftal-SpasDrotin-MDrotikind-MSpasmonil Plus
- Other names
- drotaverine + mefenamic acid
02
Targets
PDE4 (Phosphodiesterase 4A1)PGHS-1 (Prostaglandin G/H Synthase 1)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on mefenamic acid + drotaverine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mefenamic acid + drotaverine.